The clinical, cardiovascular and neuroendocrine profile of ampreloxetine showed target engagement of residual peripheral autonomic neurons and a sustained standing blood pressure effect, which is ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...